US Patent Issued to AvenCell Europe on Sept. 29 for "Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders" (German Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,277, issued on Sept. 29, was assigned to AvenCell Europe GmbH (Dresden, Germany).

"Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders" was invented by Michael Bachmann (Kelkheim, Germany) and Armin Ehninger (Dresden, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer."

The patent was filed on Feb. 21, 2020, under Application No. 16/798,255.

*For ...